Tag
This article reviews a multicenter study comparing outcomes of different treatment approaches for gastric cancer patients with positive peritoneal cytology (CY1) and/or localized peritoneal metastasis (P1a), highlighting the superior surviv
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
A Cochrane review of nine RCTs (829 patients) found low‑certainty signals that intraperitoneal chemotherapy (mainly HIPEC) may improve overall survival in high‑risk and metastatic gastric cancer, but evidence is very uncertain due to bias,
